4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). PURPOSE: To assess safety, reason for switching, compliance with the protocol and with the criteria for use. MATE...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Hosp Pharm
Main Authors: Arias, A, Blanc, R Menárguez, Torrón, A Martínez, Fernández, C Carriles, María, MC Rosado, Roces, L Velasco, García, I Zapico, Lozano-Blázquez, A
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535247/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.257
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki